FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Richard Pazdur, Hongshan Li et al.|Clinical Cancer Research|2015Cited by 532
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E MutationGeoffrey Kim, Richard Pazdur, Amy E. McKee et al.|Clinical Cancer Research|2014Cited by 215
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L. Suzman, Julia A. Beaver, Sundeep Agrawal et al.|The Oncologist|2018Cited by 200
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These DrugsGwynn Ison, Richard Pazdur, Julia A. Beaver et al.|Clinical Cancer Research|2016Cited by 80
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Richard Pazdur, Michael H. Brave et al.|Clinical Cancer Research|2016Cited by 54